United Laboratories International Holdings (HKG:3933) dosed its first patient in China for a phase 3 trial of UBT251, the company's proposed treatment for type 2 diabetes, according to a Monday bourse filing.
The pharmaceutical company said the late-stage study will be broken into two separate studies, UNIGUIDE-1 and UNIGUIDE-2.
Both studies have a primary endpoint of monitoring the baseline change in blood glucose levels after 40 weeks. However, UNIGUIDE-2 also includes a secondary endpoint of changes in body weight, blood pressure, and blood lipid levels, as well as the baseline change in blood glucose levels after 52 weeks.